| Ident. | Authors (with country if any) | Title |
|---|
| 000027 |
JINGYI MA [Canada] ; L. Stan Leung [Canada] | Deep brain stimulation of the medial septum or nucleus accumbens alleviates psychosis-relevant behavior in ketamine-treated rats |
| 000044 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 000147 |
Marie-Anne El Khoury [France] ; Victor Gorgievski [France] ; Larissa Moutsimilli [France] ; Bruno Giros [France, Canada] ; Eleni T. Tzavara [France] | Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies |
| 000418 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's Disease: On Movement, Mood, and Madness |
| 000423 |
Mehrul Hasnain [Canada] ; W. Victor R. Vieweg [États-Unis] ; Mark S. Baron [États-Unis] ; Mary Beatty-Brooks [États-Unis] ; Antony Fernandez [États-Unis] ; Anand K. Pandurangi [États-Unis] | Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism |
| 000489 |
A. W. Zuardi [Brésil] ; J. A. S. Crippa [Brésil] ; J. E. C. Hallak [Brésil] ; J. P. Pinto [Brésil] ; M. H. N. Chagas [Brésil] ; G. G. R. Rodrigues [Brésil] ; S. M. Dursun [Canada] ; V. Tumas [Brésil] | Cannabidiol for the treatment of psychosis in Parkinson's disease |
| 000674 |
Connie Marras [Canada] ; Alexander Kopp [Canada] ; FENG QIU [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada] | Antipsychotic use in older adults with parkinson's disease |
| 000675 |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 000705 |
J. M. Miyasaki [Canada] ; K. Shannon [États-Unis] ; V. Voon [États-Unis] ; B. Ravina [États-Unis] ; G. Kleiner-Fisman [États-Unis] ; K. Anderson [États-Unis] ; L. M. Shulman [États-Unis] ; G. Gronseth [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Evaluation and treatment of depression, psychosis, and dementia in parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000710 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 000771 |
Valerie Voon [Canada] ; Jean Saint-Cyr ; Andres M. Lozano ; Elena Moro ; YU YAN POON ; Anthony E. Lang | Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery |
| 000B36 |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| 000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 000B72 |
P. Seeman [Canada] ; D. Nam [Canada] ; C. Ulpian [Canada] ; I. S. C. Liu [Canada] ; T. Tallerico [Canada] | New dopamine receptor, D2Longer, with unique TG splice site, in human brain |
| 000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000C47 |
T. Mendis [Canada] ; O. Suchowersky [Canada] ; A. Lang [Canada] ; S. Gauthier [Canada] | Management of Parkinson's disease : A review of current and new therapies |
| 000D51 |
L. Thorpe [Canada] | The treatment of psychotic disorders in late life |
| 000E13 |
P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
| 000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
| 000E72 |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
| 000E92 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 000F49 |
R. W. Lam [Canada] | Chronic schizophrenia and idiopathic Parkinson's disease |
| 001019 |
J. A. Jesberger ; J. S. Richardson | Oxygen free radicals and brain dysfunction |
| 001067 |
P. Seeman ; H. B. Niznik | Dopamine receptors and transporters in Parkinson's disease and schizophrenia |
| 001106 |
T. A. Hurwitz ; D. B. Calne ; K. Waterman | Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy |
| 001182 |
M. Takada ; T. Hattori | Collateral projections from the substantia nigra to the cingulate cortex and striatum in the rat |
